ACTU

Actuate TherapeuticsN/A

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

No material screener or newswire events are stored for this ticker yet.

Sentiment decomposition

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

2026-05-11

23%

External coverage

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

2026-04-14

23%

External coverage

Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y

2026-02-06

23%

External coverage

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

2025-09-22

23%

External coverage

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

2025-05-06

23%

External coverage

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

2025-03-27

38%

External coverage

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

2024-11-12

38%

External coverage

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

2024-09-11

38%

External coverage

As of 2026-05-11 • Updated scheduledSource: News desk